You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said that the financing will go toward sales and marketing, as well as R&D on its Panorama NIPT, diagnostic tests for cancer, and clinical trials.
Co-founder Jennifer Doudna joins Fidelity Biosciences, Novartis, Mission Bay Capital, and 5 Prime Ventures as investors in the genome editing technology firm.
The company is planning to use the funds to gain CLIA certification for a new clinical lab and conduct additional studies for its cancer diagnostics.
The proceeds will be used to fund development of a molecular diagnostics platform and for clinical trials to gain FDA approval for the platform.
The firm, which previously raised $6 million, said there were 24 investors in the private offering of equity financing.
The financing is an extension of a Series E round completed in early 2014 and brings the total amount in the round to $20 million.
The financing round is the first by the Indian firm since its founding two years ago and will go toward scaling up its operations.
The company is offering about 3.6 million shares of its common stock, and warrants to purchase 715,000 shares of its stock.
The firm said in an SEC filing that it is targeting $1.5 million in the financing round and nine investors participated in the round.
The previously undisclosed Series A Round financing was led by Sequoia Capital, Mayo Clinic, and Mayo Ventures.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.